1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
Google Scholar | Crossref | Medline2. Kitamura, Y, Shimizu, K, Nagahama, M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999; 84: 4043–4049.
Google Scholar | Crossref | Medline3. Nagaiah, G, Hossain, A, Mooney, CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011; 2011: 542358.
Google Scholar | Crossref | Medline4. Pereira, M, Williams, VL, Hallanger Johnson, J, et al. Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations. Thyroid 2020; 30: 1132–1140.
Google Scholar | Crossref | Medline5. Lin, B, Ma, H, Ma, M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 2019; 11: 5888–5896.
Google Scholar | Medline6. Voutilainen, PE, Multanen, M, Haapiainen, RK, et al. Anaplastic thyroid carcinoma survival. World J Surg 1999; 23: 975–979.
Google Scholar | Crossref | Medline7. Augustin, T, Oliinyk, D, Köhler, VF, et al. Clinical outcome and toxicity in the treatment of anaplastic thyroid cancer in elderly patients. J Clin Med 2020; 9: 3231.
Google Scholar | Crossref8. Cabanillas, ME, Ryder, M, Jimenez, C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev 2019; 40: 1573–1604.
Google Scholar | Crossref | Medline9. Maniakas, A, Dadu, R, Busaidy, NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol 2020; 6: 1397–1404.
Google Scholar | Crossref | Medline10. Landa, I, Ibrahimpasic, T, Boucai, L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016; 126: 1052–1066.
Google Scholar | Crossref | Medline11. Salerno, P, De Falco, V, Tamburrino, A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metabol 2010; 95: 450–455.
Google Scholar | Crossref | Medline12. Ouyang, B, Knauf, JA, Smith, EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006; 12: 1785–1793.
Google Scholar | Crossref | Medline13. Nucera, C, Nehs, MA, Nagarkatti, SS, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 2011; 16: 296–309.
Google Scholar | Crossref | Medline14. Lim, AM, Taylor, GR, Fellowes, A, et al. BRAF inhibition in BRAFV600E-positive anaplastic thyroid carcinoma. J Natl Compr Canc Netw 2016; 14: 249–254.
Google Scholar | Crossref | Medline15. Rothenberg, SM, McFadden, DG, Palmer, EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 2015; 21: 1028–1035.
Google Scholar | Crossref | Medline16. Iravani, A, Solomon, B, Pattison, DA, et al. Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid 2019; 29: 1634–1645.
Google Scholar | Crossref | Medline17. Falchook, GS, Millward, M, Hong, D, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2015; 25: 71–77.
Google Scholar | Crossref | Medline18. Falchook, GS, Long, GV, Kurzrock, R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893–1901.
Google Scholar | Crossref | Medline19. McFadden, DG, Vernon, A, Santiago, PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci USA 2014; 111: E1600–E1609.
Google Scholar | Crossref | Medline20. Shah, MH, Wei, L, Wirth, LJ, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol 2017; 35: 6022.
Google Scholar | Crossref21. Subbiah, V, Kreitman, RJ, Wainberg, ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018; 36: 7–13.
Google Scholar | Crossref | Medline22. Iyer, PC, Dadu, R, Ferrarotto, R, et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 2018; 28: 79–87.
Google Scholar | Crossref | Medline23. Wirth, LJ, Sherman, E, Robinson, B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. New Engl J Med 2020; 383: 825–835.
Google Scholar | Crossref | Medline24. Hong, DS, DuBois, SG, Kummar, S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21: 531–540.
Google Scholar | Crossref | Medline25. Cabanillas, ME, Drilon, A, Farago, AF, et al. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer. Ann Oncol 2020; 31: S1086.
Google Scholar | Crossref26. Doebele, RC, Drilon, A, Paz-Ares, L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21: 271–282.
Google Scholar | Crossref | Medline27. Schlumberger, M, Tahara, M, Wirth, LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New Engl J Med 2015; 372: 621–630.
Google Scholar | Crossref | Medline28. Tahara, M, Kiyota, N, Yamazaki, T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol 2017; 7: 25.
Google Scholar | Crossref | Medline29. Zhang, GQ, Wei, WJ, Song, HJ, et al. Programmed cell death-ligand 1 overexpression in thyroid cancer. Endocr Pract 2019; 25: 279–286.
Google Scholar | Crossref | Medline30. Cabanillas, ME, Ferrarotto, R, Garden, AS, et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 2018; 28: 945–951.
Google Scholar | Crossref | Medline31. Cabanillas, ME, Dadu, R, Iyer, P, et al. Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 2020; 30: 1288–1296.
Google Scholar | Crossref | Medline32. Owen, DH, Konda, B, Sipos, J, et al. KRAS G12V mutation in acquired resistance to combined BRAF and MEK inhibition in papillary thyroid cancer. J Natl Compr Canc Netw 2019; 17: 409–413.
Google Scholar | Crossref | Medline33. Wang, JR, Zafereo, ME, Dadu, R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 2019; 29: 1036–1043.
Google Scholar | Crossref | Medline34. Kollipara, R, Schneider, B, Radovich, M, et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist 2017; 22: 1149–1151.
Google Scholar | Crossref | Medline35. Brauner, E, Gunda, V, Vanden Borre, P, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 2016; 7: 17194–17211.
Google Scholar | Crossref | Medline36. Cantara, S, Bertelli, E, Occhini, R, et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 2019; 64: 122–129.
Google Scholar | Crossref | Medline37. Capdevila, J, Wirth, LJ, Ernst, T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 2020; 38: 2620–2627.
Google Scholar | Crossref | Medline38. Iyer, PC, Dadu, R, Gule-Monroe, M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 2018; 6: 68.
Google Scholar | Crossref | Medline39. Cabanillas, ME, Dadu, R, Ferrarotto, R, et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). J Clin Oncol 2020; 38: 6514.
Google Scholar | Crossref40. Kunstman, JW, Juhlin, CC, Goh, G, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 2015; 24: 2318–2329.
Google Scholar | Crossref | Medline41. Pozdeyev, N, Gay, LM, Sokol, ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res 2018; 24: 3059–3068.
Google Scholar | Crossref | Medline42. Xu, B, Fuchs, T, Dogan, S, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 2020; 30: 1505–1517.
Google Scholar | Crossref | Medline43. Andreev-Drakhlin, A, Cabanillas, M, Amini, B, et al. Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-mutant medullary thyroid cancer with extensive CNS metastases. JCO Precis Oncol 2020; 4: PO.20.00096.
Google Scholar | Medline44. Dias-Santagata, D, Lennerz, JK, Sadow, PM, et al. Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma. Thyroid 2020; 30: 1384–1389.
Google Scholar | Crossref | Medline45. Okamura, R, Boichard, A, Kato, S, et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018; 2018: PO.18.00183.
Google Scholar | Medline46. Chu, Y-H, Dias-Santagata, D, Farahani, AA, et al. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol 2020; 33: 2186–2197.
Google Scholar | Crossref | Medline47. Brose, MS, Worden, FP, Newbold, KL, et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol 2017; 35: 2692–2699.
Google Scholar | Crossref | Medline48. Takahashi, S, Kiyota, N, Yamazaki, T, et al. A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 2019; 15: 717–726.
Google Scholar | Crossref | Medline49. Koyama, S, Miyake, N, Fujiwara, K, et al. Lenvatinib for anaplastic thyroid cancer and lenvatinib-induced thyroid dysfunction. Eur Thyroid J 2018; 7: 139–144.
Google Scholar | Crossref | Medline50. Brose, MS, Nutting, CM, Jarzab, B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319–328.
Google Scholar | Crossref | Medline